Biogen (BIIB), a leading pharmaceutical company, experienced nearly
30% growth in the last year, despite facing a series of challenges. They managed to bolster their
Immunology portfolio by acquiring the biotech firm,
HI-Bio, and plan to use this acquisition to enhance their< b> rare disease pipeline. They have been involved in a series of
investor lawsuits and have raised concerns about their level of debt. Biogen's performance was also boosted as their partner started making filings for their
Leqembi SC Autoinjector. Their latest
Q3 earnings report is highly anticipated. They extensively outperformed market predictions as cost cut measures took effect, and the launch of their
Alzheimer's drug,
Leqembi, gained momentum. The company is currently facing doubts about the future and ended the development of their
ALS Drug. However, their stock surged after the FDA delayed their decision on Eli Lilly's Alzheimer's treatment. Though they plan to stop selling their Alzheimer's drug,
Aduhelm, in favor of other pipeline drugs.
Biogen BIIB News Analytics from Fri, 12 Jan 2024 08:00:00 GMT to Sun, 26 May 2024 18:52:42 GMT -
Rating 6
- Rumor -3
